JP2006316040A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006316040A5 JP2006316040A5 JP2005310518A JP2005310518A JP2006316040A5 JP 2006316040 A5 JP2006316040 A5 JP 2006316040A5 JP 2005310518 A JP2005310518 A JP 2005310518A JP 2005310518 A JP2005310518 A JP 2005310518A JP 2006316040 A5 JP2006316040 A5 JP 2006316040A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- antibody
- subject
- chemotherapeutic agent
- her2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 123
- 239000002246 antineoplastic agent Substances 0.000 claims 31
- 229940127089 cytotoxic agent Drugs 0.000 claims 31
- 229940022353 herceptin Drugs 0.000 claims 26
- 229960000575 trastuzumab Drugs 0.000 claims 24
- 238000000034 method Methods 0.000 claims 21
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 18
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 18
- 230000000683 nonmetastatic effect Effects 0.000 claims 17
- 206010028980 Neoplasm Diseases 0.000 claims 16
- 230000004083 survival effect Effects 0.000 claims 16
- 201000011510 cancer Diseases 0.000 claims 14
- 208000017891 HER2 positive breast carcinoma Diseases 0.000 claims 12
- 229930012538 Paclitaxel Natural products 0.000 claims 10
- 229960001592 paclitaxel Drugs 0.000 claims 10
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 10
- 206010061819 Disease recurrence Diseases 0.000 claims 9
- 238000002512 chemotherapy Methods 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 238000011470 radical surgery Methods 0.000 claims 7
- 238000009098 adjuvant therapy Methods 0.000 claims 6
- 210000001165 lymph node Anatomy 0.000 claims 5
- 238000001356 surgical procedure Methods 0.000 claims 5
- 206010055113 Breast cancer metastatic Diseases 0.000 claims 4
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 4
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 4
- 229960004397 cyclophosphamide Drugs 0.000 claims 4
- 229960003668 docetaxel Drugs 0.000 claims 4
- 102000015694 estrogen receptors Human genes 0.000 claims 4
- 108010038795 estrogen receptors Proteins 0.000 claims 4
- 102000003998 progesterone receptors Human genes 0.000 claims 4
- 108090000468 progesterone receptors Proteins 0.000 claims 4
- 238000011498 curative surgery Methods 0.000 claims 3
- 230000000977 initiatory effect Effects 0.000 claims 3
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 claims 2
- GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 2
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 claims 2
- 241000863480 Vinca Species 0.000 claims 2
- 229940045799 anthracyclines and related substance Drugs 0.000 claims 2
- 229940046836 anti-estrogen Drugs 0.000 claims 2
- 230000001833 anti-estrogenic effect Effects 0.000 claims 2
- 238000009175 antibody therapy Methods 0.000 claims 2
- 239000003886 aromatase inhibitor Substances 0.000 claims 2
- 229960004117 capecitabine Drugs 0.000 claims 2
- 238000004590 computer program Methods 0.000 claims 2
- 229960004679 doxorubicin Drugs 0.000 claims 2
- 239000000328 estrogen antagonist Substances 0.000 claims 2
- 229960005420 etoposide Drugs 0.000 claims 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 2
- 229960000485 methotrexate Drugs 0.000 claims 2
- 229940046159 pegylated liposomal doxorubicin Drugs 0.000 claims 2
- 150000003058 platinum compounds Chemical class 0.000 claims 2
- 230000001225 therapeutic effect Effects 0.000 claims 2
- 229960001196 thiotepa Drugs 0.000 claims 2
- 230000035899 viability Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 230000001737 promoting effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 230000001755 vocal effect Effects 0.000 claims 1
Images
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US68112505P | 2005-05-13 | 2005-05-13 |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013092728A Division JP6133668B2 (ja) | 2005-05-13 | 2013-04-25 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2013109685A Division JP2013163694A (ja) | 2005-05-13 | 2013-05-24 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006316040A JP2006316040A (ja) | 2006-11-24 |
| JP2006316040A5 true JP2006316040A5 (enExample) | 2008-12-04 |
Family
ID=37450489
Family Applications (9)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2005310518A Pending JP2006316040A (ja) | 2005-05-13 | 2005-10-25 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2013092728A Expired - Lifetime JP6133668B2 (ja) | 2005-05-13 | 2013-04-25 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2013109685A Pending JP2013163694A (ja) | 2005-05-13 | 2013-05-24 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2015140158A Withdrawn JP2015187168A (ja) | 2005-05-13 | 2015-07-14 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2017088352A Pending JP2017132806A (ja) | 2005-05-13 | 2017-04-27 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2017088351A Withdrawn JP2017132805A (ja) | 2005-05-13 | 2017-04-27 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2018200936A Pending JP2019011374A (ja) | 2005-05-13 | 2018-10-25 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2020041610A Withdrawn JP2020094061A (ja) | 2005-05-13 | 2020-03-11 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2022075920A Pending JP2022093642A (ja) | 2005-05-13 | 2022-05-02 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
Family Applications After (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013092728A Expired - Lifetime JP6133668B2 (ja) | 2005-05-13 | 2013-04-25 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2013109685A Pending JP2013163694A (ja) | 2005-05-13 | 2013-05-24 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2015140158A Withdrawn JP2015187168A (ja) | 2005-05-13 | 2015-07-14 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2017088352A Pending JP2017132806A (ja) | 2005-05-13 | 2017-04-27 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2017088351A Withdrawn JP2017132805A (ja) | 2005-05-13 | 2017-04-27 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2018200936A Pending JP2019011374A (ja) | 2005-05-13 | 2018-10-25 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2020041610A Withdrawn JP2020094061A (ja) | 2005-05-13 | 2020-03-11 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
| JP2022075920A Pending JP2022093642A (ja) | 2005-05-13 | 2022-05-02 | Ｈｅｒｃｅｐｔｉｎ（登録商標）補助療法 |
Country Status (6)
| Country | Link |
|---|---|
| US (5) | US8591897B2 (enExample) |
| JP (9) | JP2006316040A (enExample) |
| AR (4) | AR054254A1 (enExample) |
| BR (1) | BRPI0601736A (enExample) |
| CA (2) | CA2790058C (enExample) |
| MX (2) | MX383973B (enExample) |
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA9811162B (en) * | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| AU6469601A (en) | 2000-05-19 | 2001-12-03 | Genentech Inc | Gene detection assay for improving the likelihood of an effective response to anerbb antagonist cancer therapy |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| SV2006002143A (es) * | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| KR20150140417A (ko) | 2004-07-22 | 2015-12-15 | 제넨테크, 인크. | Ｈｅｒ２ 항체 조성물 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| BRPI0518086A (pt) * | 2004-12-07 | 2008-10-28 | Genentech Inc | métodos para tratamento de cáncer, métodos de avaliação de fosforilação ou ativação de her e método de identificação |
| UA94899C2 (ru) | 2005-01-21 | 2011-06-25 | Дженентек, Инк. | Фиксированное дозирование антител к her |
| CN101163503B (zh) | 2005-02-23 | 2013-05-08 | 健泰科生物技术公司 | 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活 |
| PE20070207A1 (es) | 2005-07-22 | 2007-03-09 | Genentech Inc | Tratamiento combinado de los tumores que expresan el her |
| AU2007243132B2 (en) | 2006-01-20 | 2012-09-13 | Genentech, Inc. | Anti-EphrinB2 antibodies and methods using same |
| EP1913958B1 (en) * | 2006-08-03 | 2009-12-23 | Sanofi-Aventis | Antitumor compositions containing acetylcyclopropyl docetaxel and trastuzumab |
| JP2010516741A (ja) * | 2007-01-29 | 2010-05-20 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | モルホリニルアントラサイクリンおよび抗体を含む抗腫瘍の組み合わせ |
| CN101680897B (zh) | 2007-03-02 | 2013-11-13 | 健泰科生物技术公司 | 基于低her3表达预测对her二聚化抑制剂的响应 |
| KR100972618B1 (ko) | 2007-10-19 | 2010-07-27 | 국립암센터 | 허셉틴을 이용한 유방암 진단 키트, 조성물 및 이들을이용하여 허셉틴 민감성 ｈｅｒ２ 과발현 세포를 검출하는방법 |
| WO2009086197A1 (en) * | 2007-12-20 | 2009-07-09 | Monogram Biosciences, Inc. | Her-2 diagnostic methods |
| TWI472339B (zh) | 2008-01-30 | 2015-02-11 | Genentech Inc | 包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物 |
| CA2715319A1 (en) | 2008-03-14 | 2009-09-17 | Genentech, Inc. | Genetic variations associated with drug resistance |
| CA2990929C (en) * | 2008-03-18 | 2022-04-12 | Genentech, Inc. | Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use |
| WO2009131673A1 (en) * | 2008-04-25 | 2009-10-29 | Ludwig Institute For Cancer Research Ltd. | Targeted treatment for subjects with estrogen receptor negative and progesterone receptor negative breast cancers |
| ES2342646B1 (es) * | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| BRPI0812682A2 (pt) | 2008-06-16 | 2010-06-22 | Genentech Inc | tratamento de cáncer de mama metastático |
| WO2010016527A1 (ja) | 2008-08-05 | 2010-02-11 | 東レ株式会社 | 癌の検出方法 |
| CN106039307A (zh) | 2008-08-05 | 2016-10-26 | 东丽株式会社 | 用于治疗和预防癌症的药物组合物 |
| JP2012507299A (ja) | 2008-10-31 | 2012-03-29 | バイオジェン・アイデック・エムエイ・インコーポレイテッド | Ｌｉｇｈｔ標的分子およびその使用 |
| ES2637411T3 (es) | 2008-12-01 | 2017-10-13 | Laboratory Corporation Of America Holdings | Métodos y ensayos para medir p95 Y/O p95 en una muestra y anticuerpos específicos para p95 |
| MX2011006167A (es) * | 2008-12-11 | 2011-07-28 | Abraxis Bioscience Llc | Combinaciones y modos de administracion de agentes terapeuticos y terapia de combinacion. |
| AU2010204583A1 (en) | 2009-01-15 | 2011-08-25 | Laboratory Corporation Of America Holdings | Methods of determining patient response by measurement of Her-3 |
| WO2010083463A1 (en) * | 2009-01-15 | 2010-07-22 | Laboratory Corporation Of America Holdings | Methods of determining patient response by measurement of her-2 expression |
| US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
| CN104857534A (zh) * | 2009-07-31 | 2015-08-26 | 恩多塞特公司 | 叶酸盐靶向的诊断和治疗 |
| EP2532367B1 (en) | 2010-02-04 | 2018-08-29 | Toray Industries, Inc. | Pharmaceutical agent for treatment and/or prevention of cancer |
| KR101801667B1 (ko) | 2010-02-04 | 2017-11-27 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| RU2598258C2 (ru) | 2010-02-04 | 2016-09-20 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики рака |
| EP2532365B1 (en) | 2010-02-04 | 2016-05-04 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prevention of cancer |
| KR101805520B1 (ko) | 2010-02-04 | 2017-12-07 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| HUE025678T2 (en) | 2010-02-04 | 2016-04-28 | Toray Industries | A pharmaceutical composition for the treatment and / or prevention of cancer |
| MX2013006392A (es) * | 2010-12-09 | 2013-12-06 | Genentech Inc | Tratamiento de cancer positivo para her2 con paclitaxel y trastuzumab-mcc-dm1. |
| DK3351630T3 (da) | 2011-08-04 | 2020-01-02 | Toray Industries | Farmaceutisk sammensætning omfattende anti caprin-1-antistoffer til behandling og/eller forebyggelse af cancer |
| CA2844034C (en) | 2011-08-04 | 2019-07-16 | Toray Industries, Inc. | Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| PL2740798T3 (pl) | 2011-08-04 | 2017-07-31 | Toray Industries, Inc. | Kompozycja leku do leczenia i/lub zapobiegania nowotworom |
| US9796775B2 (en) | 2011-08-04 | 2017-10-24 | Toray Industries, Inc. | Method for detecting pancreatic cancer |
| RU2610428C2 (ru) | 2011-08-04 | 2017-02-10 | Торэй Индастриз, Инк. | Фармацевтическая композиция для лечения и/или профилактики злокачественной опухоли |
| ES2609846T3 (es) | 2011-08-04 | 2017-04-24 | Toray Industries, Inc. | Composición farmacéutica para el tratamiento y/o prevención del cáncer pancreático |
| TR201802089T4 (tr) | 2011-08-04 | 2018-03-21 | Toray Industries | Kanserin tedavisi ve/veya önlenmesi amacına yönelik ilaç bileşimi. |
| DK4234033T3 (da) * | 2011-10-14 | 2025-03-31 | Hoffmann La Roche | Anvendelser for og fremstillet artikel indbefattende HER2-dimeriseringshæmmeren pertuzumab |
| US9573993B2 (en) | 2012-02-21 | 2017-02-21 | Toray Industries, Inc. | Pharmaceutical composition for treatment of cancer comprising an anti-CAPRIN-1 peptide antibody |
| DK2818482T3 (da) | 2012-02-21 | 2019-07-15 | Toray Industries | Farmaceutisk sammensætning til behandling af cancer |
| KR102009236B1 (ko) | 2012-02-21 | 2019-08-09 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| PT2818481T (pt) | 2012-02-21 | 2019-10-25 | Toray Industries | Composição farmacêutica para tratamento e/ou prevenção de cancro |
| PL2832366T3 (pl) | 2012-03-30 | 2018-04-30 | Toray Industries, Inc. | Kompozycja farmaceutyczna do leczenia i/lub zapobiegania rakowi pęcherzyka żółciowego |
| HUE036424T2 (hu) | 2012-03-30 | 2018-07-30 | Toray Industries | Gyógyászati készítmény májrák kezelésére és/vagy megelõzésére |
| PL2876446T3 (pl) | 2012-07-19 | 2019-06-28 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| PL2876447T3 (pl) | 2012-07-19 | 2020-05-18 | Toray Industries, Inc. | Sposób wykrywania nowotworu |
| EP2907824B1 (en) | 2012-10-11 | 2018-04-11 | Daiichi Sankyo Company, Limited | Antibody-drug conjugate |
| WO2014169067A1 (en) * | 2013-04-09 | 2014-10-16 | Merrimack Pharmaceuticals, Inc. | Compositions for improving outcomes of liposomal chemotherapy |
| SG11201508536PA (en) | 2013-04-16 | 2015-11-27 | Genentech Inc | Pertuzumab variants and evaluation thereof |
| KR102255616B1 (ko) | 2013-08-09 | 2021-05-25 | 도레이 카부시키가이샤 | 암의 치료 및/또는 예방용 의약 조성물 |
| SMT202100659T1 (it) * | 2014-01-31 | 2022-01-10 | Daiichi Sankyo Co Ltd | Coniugato anticorpo anti-her2-farmaco |
| SG10201809411PA (en) | 2014-04-25 | 2018-11-29 | Genentech Inc | Methods of treating early breast cancer with trastuzumab-mcc-dm1 and pertuzumab |
| TWI695011B (zh) | 2014-06-18 | 2020-06-01 | 美商梅爾莎納醫療公司 | 抗ｈｅｒ２表位之單株抗體及其使用之方法 |
| WO2015195925A1 (en) | 2014-06-18 | 2015-12-23 | Mersana Therapeutics, Inc. | Protein-polymer-drug conjugates and methods of using same |
| EP3302551B1 (en) | 2015-05-30 | 2024-06-26 | F. Hoffmann-La Roche AG | Methods of treating her2-positive previously untreated metastatic breast cancer |
| CA2990465A1 (en) | 2015-07-07 | 2017-01-12 | Genentech, Inc. | Combination therapy with an anti-her2 antibody-drug conjugate and a bcl-2 inhibitor |
| US11554138B2 (en) | 2015-07-16 | 2023-01-17 | The University Of Hong Kong | Bismuth(III) complexes as adjuvants in the treatment of cancer using platinum-based chemotherapy |
| WO2017087280A1 (en) | 2015-11-16 | 2017-05-26 | Genentech, Inc. | Methods of treating her2-positive cancer |
| WO2018026794A1 (en) * | 2016-08-02 | 2018-02-08 | Curirx Inc. | Methods for the preparation of liposomes |
| MX394860B (es) | 2016-09-27 | 2025-03-24 | Vertex Pharma | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). |
| CN110099926A (zh) | 2016-12-28 | 2019-08-06 | 豪夫迈·罗氏有限公司 | 晚期her2表达性癌症的治疗 |
| HUE052551T2 (hu) | 2017-01-17 | 2021-05-28 | Genentech Inc | Szubkután HER2 antitest készítmények |
| ES2955074T3 (es) | 2017-02-20 | 2023-11-28 | Dragonfly Therapeutics Inc | Proteínas que se unen a HER2, NKG2D Y CD16 |
| US11077189B2 (en) | 2017-03-02 | 2021-08-03 | Genentech Inc. | Adjuvant treatment of HER2-positive breast cancer |
| WO2018200505A1 (en) | 2017-04-24 | 2018-11-01 | Genentech, Inc. | Erbb2/her2 mutations in the transmbrane or juxtamembrane domain |
| CN111278894A (zh) | 2017-07-06 | 2020-06-12 | 学校法人京都药科大学 | 肾脏靶向药物递送载体 |
| ES2986967T3 (es) | 2018-02-08 | 2024-11-13 | Dragonfly Therapeutics Inc | Combinaciones de dominios variables de anticuerpos dirigidas al receptor NKG2D |
| EA202091888A1 (ru) | 2018-08-08 | 2020-10-23 | Драгонфлай Терапьютикс, Инк. | Вариабельные домены антител, нацеленные на рецептор nkg2d |
| CN109739435B (zh) * | 2018-12-03 | 2023-10-13 | 中科恒运股份有限公司 | 文件存储和更新方法及装置 |
| KR20230030621A (ko) | 2020-06-29 | 2023-03-06 | 제넨테크, 인크. | 퍼투주맙 + 트라스투주맙 고정 용량 조합 |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Pharmaceutical compositions of a her2/neu antibody and use of the same |
| US12377144B2 (en) | 2021-03-03 | 2025-08-05 | Dragonfly Therapeutics, Inc. | Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigen |
| TW202308701A (zh) | 2021-04-29 | 2023-03-01 | 大陸商上海匯連生物醫藥有限公司 | 抗體偶聯藥物的製備方法及應用 |
| WO2022262789A1 (zh) | 2021-06-17 | 2022-12-22 | 明慧医药（杭州）有限公司 | 一种抗肿瘤化合物及其应用 |
| WO2023139293A1 (en) | 2022-01-24 | 2023-07-27 | Novimmune Sa | Composition and methods for the selective activation of cytokine signaling pathways |
| WO2023174925A1 (en) | 2022-03-14 | 2023-09-21 | Novimmune Sa | Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells |
| CN119055767A (zh) * | 2023-05-09 | 2024-12-03 | 上海津曼特生物科技有限公司 | 包含抗her2双特异性抗体的联合治疗药物及其用途 |
| WO2025019254A1 (en) | 2023-07-14 | 2025-01-23 | Guardant Health, Inc. | Classification of breast tumors using dna methylation from liquid biopsy |
Family Cites Families (92)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4935341A (en) | 1986-06-04 | 1990-06-19 | Whitehead Institute For Biomedical Research | Detection of point mutations in neu genes |
| US7838216B1 (en) | 1986-03-05 | 2010-11-23 | The United States Of America, As Represented By The Department Of Health And Human Services | Human gene related to but distinct from EGF receptor gene |
| US5401638A (en) | 1986-06-04 | 1995-03-28 | Oncogene Science, Inc. | Detection and quantification of neu related proteins in the biological fluids of humans |
| US4968603A (en) | 1986-12-31 | 1990-11-06 | The Regents Of The University Of California | Determination of status in neoplastic disease |
| US5824311A (en) | 1987-11-30 | 1998-10-20 | Trustees Of The University Of Pennsylvania | Treatment of tumors with monoclonal antibodies against oncogene antigens |
| US5720937A (en) | 1988-01-12 | 1998-02-24 | Genentech, Inc. | In vivo tumor detection assay |
| WO1989006692A1 (en) | 1988-01-12 | 1989-07-27 | Genentech, Inc. | Method of treating tumor cells by inhibiting growth factor receptor function |
| DK0474727T3 (da) | 1989-05-19 | 1998-01-12 | Genentech Inc | HER2 ekstracellulært domæne |
| US5705157A (en) | 1989-07-27 | 1998-01-06 | The Trustees Of The University Of Pennsylvania | Methods of treating cancerous cells with anti-receptor antibodies |
| US6884418B1 (en) | 1989-08-04 | 2005-04-26 | Berlex Laboratories, Inc. | Use of ligand-mimicking agents and anti-neoplastic drugs in cancer therapy |
| ATE207958T1 (de) | 1989-08-04 | 2001-11-15 | Schering Ag | Äusserliche domäne von c-erbb-2:gp75 |
| US5183884A (en) | 1989-12-01 | 1993-02-02 | United States Of America | Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| IL101943A0 (en) | 1991-05-24 | 1992-12-30 | Genentech Inc | Structure,production and use of heregulin |
| AU675916B2 (en) | 1991-06-14 | 1997-02-27 | Genentech Inc. | Method for making humanized antibodies |
| US6800738B1 (en) | 1991-06-14 | 2004-10-05 | Genentech, Inc. | Method for making humanized antibodies |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| US5939531A (en) | 1991-07-15 | 1999-08-17 | Novartis Corp. | Recombinant antibodies specific for a growth factor receptor |
| US5514554A (en) | 1991-08-22 | 1996-05-07 | Becton Dickinson And Company | Methods and compositions for cancer therapy and for prognosticating responses to cancer therapy |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US5288477A (en) | 1991-09-27 | 1994-02-22 | Becton, Dickinson And Company | Method for prognosticating response to cancer therapy |
| FI941572L (fi) * | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993016185A2 (en) | 1992-02-06 | 1993-08-19 | Creative Biomolecules, Inc. | Biosynthetic binding protein for cancer marker |
| WO1994009022A1 (en) | 1992-10-09 | 1994-04-28 | Oncor, Inc. | Methods for the detection of chromosome structural abnormalities by in situ hybridization to fixed tissue |
| US6733752B1 (en) * | 1994-03-30 | 2004-05-11 | The Trustees Of The University Of Pennsylvania | Prevention of tumors with monoclonal antibodies against neu |
| US20030108545A1 (en) | 1994-02-10 | 2003-06-12 | Patricia Rockwell | Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist |
| US6811779B2 (en) | 1994-02-10 | 2004-11-02 | Imclone Systems Incorporated | Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy |
| US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
| US5846749A (en) | 1994-10-12 | 1998-12-08 | The Regents Of The University Of California | Quantitative measurement of tissue protein identified by immunohistochemistry and standardized protein determination |
| US5804396A (en) | 1994-10-12 | 1998-09-08 | Sugen, Inc. | Assay for agents active in proliferative disorders |
| US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
| US5783404A (en) | 1995-04-13 | 1998-07-21 | Amgen Inc. | Methods and compositions for determining HER-2/neu expression using monoclonal antibodies |
| US6410690B1 (en) | 1995-06-07 | 2002-06-25 | Medarex, Inc. | Therapeutic compounds comprised of anti-Fc receptor antibodies |
| EP2258726A1 (en) | 1995-06-14 | 2010-12-08 | The Regents of the University of California | High affinity human antibodies to c-erbB-2 |
| US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US5925519A (en) | 1996-06-03 | 1999-07-20 | The Regents Of The University Of California | Genetic alterations associated with prostate cancer |
| US5922845A (en) | 1996-07-11 | 1999-07-13 | Medarex, Inc. | Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies |
| ES2335365T3 (es) | 1996-11-27 | 2010-03-25 | Genentech, Inc. | Purificacion por afinidad de polipeptido en una matriz de proteina a. |
| US5994071A (en) | 1997-04-04 | 1999-11-30 | Albany Medical College | Assessment of prostate cancer |
| US20020076695A1 (en) | 1997-04-04 | 2002-06-20 | Jeffrey S. Ross | Methods for treating prostate cancer |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US6358682B1 (en) | 1998-01-26 | 2002-03-19 | Ventana Medical Systems, Inc. | Method and kit for the prognostication of breast cancer |
| US20020192211A1 (en) | 1998-03-17 | 2002-12-19 | Hudziak Robert M. | Method of treating tumor cells by inhibiting growth factor receptor function |
| CA2324494A1 (en) | 1998-03-27 | 1999-09-30 | Genentech, Inc. | Apo-2 ligand-anti-her-2 antibody synergism |
| ES2261589T3 (es) | 1998-05-06 | 2006-11-16 | Genentech, Inc. | Composicion de anticuerpos anti-her2. |
| SE512710C2 (sv) | 1998-07-08 | 2000-05-02 | Ericsson Telefon Ab L M | Kapsel för högeffekttransistorchip för höga frekvenser innefattande en elektriskt och termiskt ledande fläns |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| WO2000044225A1 (en) | 1999-01-27 | 2000-08-03 | Cornell Research Foundation, Inc. | TREATING CANCERS ASSOCIATED WITH OVEREXPRESSION OF HER-2/neu |
| US6333348B1 (en) | 1999-04-09 | 2001-12-25 | Aventis Pharma S.A. | Use of docetaxel for treating cancers |
| EP1187632B1 (en) * | 1999-05-14 | 2008-12-03 | Genentech, Inc. | TREATMENT WITH ANTI-ErbB2 ANTIBODIES |
| JP3485252B2 (ja) | 1999-06-16 | 2004-01-13 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 情報処理方法、情報端末支援サーバ、コラボレーション・システム、情報処理プログラムを格納する記憶媒体 |
| US20030086924A1 (en) | 1999-06-25 | 2003-05-08 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| US6949245B1 (en) * | 1999-06-25 | 2005-09-27 | Genentech, Inc. | Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies |
| US20040013667A1 (en) | 1999-06-25 | 2004-01-22 | Genentech, Inc. | Treatment with anti-ErbB2 antibodies |
| HU230586B1 (hu) * | 1999-06-25 | 2017-02-28 | Genentech, Inc. | Anti-ErbB antitest/maytansinoid konjugátumok alkalmazása rákos betegségek kezelésére szolgáló gyógyszer előállítására |
| MXPA02002037A (es) * | 1999-08-27 | 2002-10-31 | Genentech Inc | Dosificaciones para el tratamiento con anticuerpos anti-erb2. |
| US7303749B1 (en) | 1999-10-01 | 2007-12-04 | Immunogen Inc. | Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents |
| EP2289549A3 (en) | 1999-10-01 | 2011-06-15 | Immunogen, Inc. | Immunoconjugates for treating cancer |
| WO2001064246A2 (en) | 2000-02-29 | 2001-09-07 | Janssen Pharmaceutica N.V. | Farnesyl protein transferase inhibitor combinations with an her2 antibody |
| US6632979B2 (en) | 2000-03-16 | 2003-10-14 | Genentech, Inc. | Rodent HER2 tumor model |
| US7097840B2 (en) * | 2000-03-16 | 2006-08-29 | Genentech, Inc. | Methods of treatment using anti-ErbB antibody-maytansinoid conjugates |
| US6767541B2 (en) | 2000-03-20 | 2004-07-27 | The Regents Of The University Of California | HER-2/neu overexpression abrogates growth inhibitory pathways |
| US20030152572A1 (en) | 2000-04-06 | 2003-08-14 | Yoshimi Homma | Diagnostic and therapeutic agents for rheumatoid arthritis |
| GB0008368D0 (en) | 2000-04-06 | 2000-05-24 | Astrazeneca Ab | Combination product |
| US7306801B2 (en) | 2000-05-15 | 2007-12-11 | Health Research, Inc. | Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein |
| AU6469601A (en) | 2000-05-19 | 2001-12-03 | Genentech Inc | Gene detection assay for improving the likelihood of an effective response to anerbb antagonist cancer therapy |
| TWI317285B (en) | 2000-07-28 | 2009-11-21 | Dainippon Sumitomo Pharma Co | New use and kit for remedies for cancer |
| US6984494B2 (en) | 2000-08-15 | 2006-01-10 | Genentech, Inc. | Analytical method |
| NZ546251A (en) | 2000-12-01 | 2008-01-31 | Response Genetics Inc | Method of determining epidermal growth factor receptor gene expression in a parafin embedded tiasue sample and correlation of levels thereof with survival rates |
| US7005278B2 (en) | 2001-03-02 | 2006-02-28 | Danenberg Kathleen D | Method of determining dihydropyrimidine dehydrogenase gene expression |
| US6582919B2 (en) | 2001-06-11 | 2003-06-24 | Response Genetics, Inc. | Method of determining epidermal growth factor receptor and HER2-neu gene expression and correlation of levels thereof with survival rates |
| US6602670B2 (en) | 2000-12-01 | 2003-08-05 | Response Genetics, Inc. | Method of determining a chemotherapeutic regimen based on ERCC1 expression |
| US20020142328A1 (en) | 2000-12-01 | 2002-10-03 | Danenberg Kathleen D. | Method of determining a chemotherapeutic regimen by assaying gene expression in primary tumors |
| WO2002045653A2 (en) | 2000-12-08 | 2002-06-13 | Uab Research Foundation | Combination radiation therapy and chemotherapy in conjuction with administration of growth factor receptor antibody |
| US20040138160A1 (en) | 2001-04-27 | 2004-07-15 | Kenichiro Naito | Preventive/therapeutic method for cancer |
| US20030068318A1 (en) | 2001-09-28 | 2003-04-10 | O'brien Timothy | Treatment of uterine serous papillary cancer |
| US20030175845A1 (en) | 2002-03-13 | 2003-09-18 | Kalbag Suresh M. | Use of sulfitolysis in high performance peptide mapping |
| US20030190689A1 (en) | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
| JP2005522514A (ja) | 2002-04-10 | 2005-07-28 | ジェネンテック・インコーポレーテッド | 抗ｈｅｒ２抗体改変体 |
| ITTO20020340A1 (it) | 2002-04-19 | 2003-10-20 | Biother Di Contardi Gabriella | Localizzazione del recettore her2 mediante anticorpo umanizzato biotinilato. |
| US20030202973A1 (en) | 2002-04-29 | 2003-10-30 | Dr. George Pieczenik | Treatment of refractory human tumors with epidermal growth factor receptor and HER1 mitogenic ligand (EGFRML) antagonists |
| CA2486124A1 (en) | 2002-05-17 | 2003-11-27 | Aventis Pharma S.A. | Use of docetaxel/doxorubicin/cyclophosphamide in adjuvant therapy of breast and ovarian cancer |
| DK2263691T3 (da) | 2002-07-15 | 2012-10-22 | Hoffmann La Roche | Behandling af cancer med det rekombinante humaniserede monoklonale anti-ErbB2-antistof 2C4 (rhuMAb-2C4) |
| US20040013297A1 (en) | 2002-07-18 | 2004-01-22 | Roger Lo | Method for performing color gamut compression |
| HUE033623T2 (en) | 2002-09-11 | 2017-12-28 | Genentech Inc | protein purification |
| CA2506320A1 (en) | 2002-11-21 | 2004-06-10 | Genentech, Inc. | Therapy of non-malignant diseases or disorders with anti-erbb2 antibodies |
| US20040231909A1 (en) | 2003-01-15 | 2004-11-25 | Tai-Yang Luh | Motorized vehicle having forward and backward differential structure |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| NZ543498A (en) * | 2003-05-14 | 2007-06-29 | Immunogen Inc | A conjugate comprising an antibody chemically coupled to a maytansinoid |
| CN114053429A (zh) | 2004-06-01 | 2022-02-18 | 健泰科生物技术公司 | 抗体-药物偶联物和方法 |
-
2005
- 2005-10-25 JP JP2005310518A patent/JP2006316040A/ja active Pending
-
2006
- 2006-03-21 CA CA2790058A patent/CA2790058C/en active Active
- 2006-03-21 CA CA2540547A patent/CA2540547C/en active Active
- 2006-04-06 US US11/400,638 patent/US8591897B2/en active Active
- 2006-04-21 MX MX2018000183A patent/MX383973B/es unknown
- 2006-04-21 MX MX2013009514A patent/MX344809B/es unknown
- 2006-04-21 AR AR20060101586A patent/AR054254A1/es unknown
- 2006-04-25 BR BRPI0601736-3A patent/BRPI0601736A/pt not_active Application Discontinuation
-
2011
- 2011-08-08 US US13/205,523 patent/US8597654B2/en active Active
-
2012
- 2012-10-03 AR ARP120103682A patent/AR088110A2/es unknown
-
2013
- 2013-04-25 JP JP2013092728A patent/JP6133668B2/ja not_active Expired - Lifetime
- 2013-05-24 JP JP2013109685A patent/JP2013163694A/ja active Pending
- 2013-10-25 US US14/063,885 patent/US20140086940A1/en not_active Abandoned
-
2015
- 2015-07-14 JP JP2015140158A patent/JP2015187168A/ja not_active Withdrawn
-
2017
- 2017-02-09 US US15/428,807 patent/US20180236093A1/en not_active Abandoned
- 2017-04-27 JP JP2017088352A patent/JP2017132806A/ja active Pending
- 2017-04-27 JP JP2017088351A patent/JP2017132805A/ja not_active Withdrawn
- 2017-05-15 AR ARP170101287A patent/AR109246A2/es unknown
- 2017-05-17 AR ARP170101322A patent/AR108615A2/es unknown
-
2018
- 2018-10-25 JP JP2018200936A patent/JP2019011374A/ja active Pending
-
2020
- 2020-01-30 US US16/777,345 patent/US20200155701A1/en not_active Abandoned
- 2020-03-11 JP JP2020041610A patent/JP2020094061A/ja not_active Withdrawn
-
2022
- 2022-05-02 JP JP2022075920A patent/JP2022093642A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006316040A5 (enExample) | ||
| Rechoum et al. | AR collaborates with ERα in aromatase inhibitor-resistant breast cancer | |
| Piccart et al. | Phase III trial comparing two dose levels of epirubicin combined with cyclophosphamide with cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer | |
| Freedman* | Follicular lymphoma: 2012 update on diagnosis and management | |
| Siebels et al. | A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients | |
| Kiesewetter et al. | A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma) | |
| Komrokji et al. | Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes | |
| Ryan et al. | Randomized phase 3 trial of abiraterone acetate in men with metastatic castration-resistant prostate cancer and no prior chemotherapy | |
| Bartsch et al. | Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study | |
| Goss | Letrozole in the extended adjuvant setting: MA. 17 | |
| Mohammadianpanah et al. | The efficacy and safety of neoadjuvant chemotherapy+/− letrozole in postmenopausal women with locally advanced breast cancer: a randomized phase III clinical trial | |
| Huszno et al. | Cardiac side effects of trastuzumab in breast cancer patients–single centere experiences | |
| Láng et al. | Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: final results of the Retreatment after HErceptin Adjuvant trial | |
| Kümmel et al. | Randomised trial: survival benefit and safety of adjuvant dose-dense chemotherapy for node-positive breast cancer | |
| Eigl et al. | A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209 | |
| Sharp et al. | A multi-centre Canadian pilot study of metronomic temozolomide combined with radiotherapy for newly diagnosed paediatric brainstem glioma | |
| Witzig et al. | A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B‐cell non‐Hodgkin lymphoma: ECOG 3402 | |
| Futamura et al. | Preoperative neoadjuvant chemotherapy using nanoparticle albumin-bound paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer: a multicenter phase II trial | |
| Bae et al. | Palliative radiotherapy in patients with a symptomatic pelvic mass of metastatic colorectal cancer | |
| Sharma et al. | PARP pioneers: using BRCA1/2 mutation-targeted inhibition to revolutionize breast cancer treatment | |
| JP6745805B2 (ja) | 乳がんの治療で使用するための抗ヒスタミン剤 | |
| Zhu et al. | Hydroxypropyl-β-cyclodextrin inhibits the development of triple negative breast cancer by enhancing antitumor immunity | |
| Chan et al. | A phase II study of high‐dose calcitriol combined with mitoxantrone and prednisone for androgen‐independent prostate cancer | |
| Wildiers et al. | Neoadjuvant capecitabine and docetaxel (plus trastuzumab): an effective non-anthracycline-based chemotherapy regimen for patients with locally advanced breast cancer | |
| Yamaguchi et al. | Mitigative efficacy of the clinical dosage administration of granulocyte colony-stimulating factor and romiplostim in mice with severe acute radiation syndrome |